
Bloomberg · Feb 27, 2026 · Collected from RSS
Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range.
February 27, 2026 at 1:04 AM UTCGenerate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range.The Somerville, Massachusetts-based drug developer sold 25 million shares for $16 each, according to a statementBloomberg Terminal Thursday. Generate was offering the shares for $15 to $17 apiece, according to its earlier filings with the US Securities and Exchange Commission. The deal was oversubscribed, people familiar with the matter have saidBloomberg Terminal.